Following a major independent review of care, policymakers are moving toward a more cautious, multidisciplinary model that places greater emphasis on developmental and mental health assessment. Within this shift, screening for neurodevelopmental conditions such as autism is emerging as a routine component of evaluation, raising new ethical and policy questions about how autism is interpreted within complex clinical pathways.

The policy transition is rooted in the findings of the Cass Review, an independent evaluation of gender identity services for children and young people commissioned by NHS England. The review concluded that the evidence base for medical interventions, including puberty blockers and hormone treatments, remains limited and uncertain in terms of long-term outcomes.¹ It also found that many young people presenting to gender services have additional needs, including mental health challenges and neurodevelopmental conditions such as autism.¹ In response, NHS England has begun implementing a new service model that embeds comprehensive assessment before any medical pathway is considered.²

Within this model, autism is not treated as a separate or downstream diagnosis but as part of an integrated clinical picture. Draft service specifications and implementation guidance indicate that young people referred to gender services may undergo screening for autism and related conditions as part of a broader biopsychosocial assessment.² If indicators are identified, referrals to specialist neurodevelopmental services may be required before further decisions are made. This reflects a structural shift toward understanding gender-related distress within a wider developmental context.

Autism prevalence is estimated at ~1%–2% in the general population, compared with ~8%–15% in youth referred to gender services. — National Autistic Society (UK); Warrier et al., Nature Communications (2020); Kallitsounaki & Williams, review of autism and gender dysphoria

The inclusion of autism screening is informed in part by research showing higher rates of autism among individuals referred to gender clinics compared to the general population. Some studies suggest that autistic traits or diagnoses may be present in a significant minority of these patients.³ However, the relationship is not causal and remains poorly understood. Current evidence indicates that autism is one of several overlapping factors—alongside anxiety, depression, and other conditions—that may co-occur in young people seeking gender-related care.⁴ This complexity has contributed to the policy emphasis on comprehensive assessment rather than single-pathway treatment.

At the same time, the integration of autism into gender service pathways introduces a set of ethical tensions. One concern is diagnostic overshadowing, in which the presence of autism may influence how clinicians interpret a young person’s reported identity or distress. Advocates have raised questions about whether autism could function, intentionally or not, as a gatekeeping mechanism that delays or limits access to care. Others argue that failing to assess neurodevelopmental conditions risks overlooking important aspects of a patient’s needs and undermining informed decision-making.

Access remains a parallel concern. The United Kingdom already faces significant waiting times for both gender services and autism assessments, with some patients waiting years for evaluation. Adding additional layers of screening may improve clinical rigor but could also extend timelines in an already constrained system. This creates a policy tradeoff between thoroughness and timeliness—one that is likely to shape implementation outcomes in the coming years.

The restructuring of services is also institutional. The closure of the Tavistock Gender Identity Development Service, previously the primary provider of youth gender care in England, marked a turning point. It is being replaced by a network of regional centers designed to deliver multidisciplinary care, integrating pediatric, mental health, and neurodevelopmental expertise.² This model reflects a broader shift toward evidence-based practice, standardized data collection, and greater clinical oversight.

The UK’s approach is already influencing international discussions. Several European countries, including Sweden and Finland, have conducted evidence reviews and adopted more cautious clinical guidance for pediatric gender care, often citing low-certainty evidence and unclear long-term outcomes.⁵ While policy frameworks differ, the emphasis on comprehensive assessment and uncertainty management is becoming more prominent across systems.

For autism policy, the central question is not whether autism should be considered within gender services, but how it should be interpreted. If used to support individualized, context-aware care, screening may enhance understanding and outcomes. If used as a simplifying explanation or barrier, it risks conflating distinct aspects of identity and development. As the NHS continues to implement its new model, the role of autism within this evolving system will remain a defining issue—both for clinical practice and for broader debates about evidence, identity, and care.

¹ NHS England, *Independent Review of Gender Identity Services for Children and Young People (Cass Review)*, 2024.
² NHS England, *Implementing the Cass Review: Children and Young People’s Gender Services*, service specifications and guidance.
³ Warrier et al., “Elevated rates of autism and other neurodevelopmental conditions in transgender and gender-diverse individuals,” *Nature Communications*, 2020.
⁴ National Autistic Society (UK), “Autism and gender identity,” overview of current evidence and clinical complexity.
⁵ Cohen, Joshua P., “Europe and U.S. Diverge on Treatment of Gender Incongruence in Minors,” *Forbes*, 2023.